

**Frontiers in Medicine:  
Delivering on the promise to end suffering and death from Cancer**

Eric P. Newman Center --- Wednesday April 26, 2006 --- 11:30am – 6:00pm

**Presented by the Siteman Cancer Center and Center for Emerging Technologies**

*Frontiers in Medicine* offers an insider's early look at major advances in medicine during the research and early development phases. This Forum will feature top researchers from Washington University's Siteman Cancer Center, a National Cancer Institute Comprehensive Cancer Center, who are working on the cutting edge of innovative approaches to cancer diagnostics and therapies. The Forum also includes two biomedical companies that are in the forefront of developing targeted cancer diagnostics and therapies and are examples of how collaborations between companies and university faculty can lead to breakthroughs in medicine.

**RSVP by April 21 to Ann at 615-6900 or [info@emergingtech.org](mailto:info@emergingtech.org)**

**11:30-1:00 Lunch with keynote speaker**

**Gregory J. Downing, D.O., Ph.D.**

Director, Center for Strategic Science and Technology Initiatives, National Cancer Institute

**Testimonial:**

**Cynthia Kramer**

Participant in a clinical trial for SGN-30, a synthetic monoclonal antibody therapy from Seattle Genetics for Anaplastic Large Cell T-cell Lymphoma.

**1:15-3:00 Targeted Genetic and Cellular Diagnostics and Therapies**

**John DiPersio, MD, PhD** – gene therapy for bone marrow transplant graft vs. host response

**Helen Piwnica-Worms, PhD** – cell cycle targeting agents in breast cancer

**Paula Fracasso, MD, PhD** – novel therapies for gynecological cancers in clinical development

**Brian Dieckgraefe, MD** – smart bombs for colorectal cancer

**Shrikant Anant, PhD** – Curcumin (from Curry) to treat gastro-intestinal disease and cancers

**Case Study: Kereos – Sam Wickline, MD and Al Beardsley**

Use of targeted nanoparticles (NPs) as highly specific molecular markers for solid tumors using MRI, for earlier diagnosis and more effective treatments.

**3:15-5:00 Cancer Genome, Epigenetics, Biomarkers and Pharmacogenomics**

**Rick Wilson, PhD** – implications from sequencing the cancer genome

**Matthew Ellis, MB, BChir, PhD** – molecular and genetic profiling for outcome predictors and novel therapeutics in breast cancer

**Tim Ley, MD** – genomic profiling of Acute Myelogenous Leukemia (AML) and predictors for success of bone marrow transplantation

**Paul Goodfellow, PhD** – relationship of DNA methylation to cancer

**Howard McLeod, PharmD** – pharmacogenomics in treatment assessment for colorectal cancer

**Case Study: Orion Genomics – Nate Lakey**

Deriving epigenetic information from gene methylation for developing oncology diagnostic products to detect abnormal patterns related to disease.

**5:00-6:00 Networking Reception**